NEW YORK (
CHANGE IN RATINGS
upgraded at Jefferies from Hold to Buy. $18 price target. Fundamentals look bad , but have likely bottomed out.
coverage resumed at BofA/Merrill. ARCC coverage resumed with a Buy rating and $16 price target. Following the Allied Capital merger, the company should benefit from synergies.
upgraded at Citi to Buy from Hold on solid pipeline progress. Price target raised to $30 from $28.
rated new Buy at Jefferies. $7 price target. Silver prices should remain high and the company is positioned well for continued growth.
upgraded at Longbow from Neutral to Buy. Higher box prices appear to have taken hold.
upgraded at Goldman to Buy. $76 price target. Stock has lagged its peers and earnings growth could accelerate in the second half of the year.
upgraded at Longbow from Neutral to Buy. Box prices are moving higher and supply remains tight.
rated new Hold at Deutsche. $57 price target. Company has long-term growth potential, but exposure to Europe could hang over the shares.
rated new Equal-weight at Morgan Stanley. Chicken market is bouncing back, but recent gains may not be sustainable.
initiated at Citi with a Buy rating as wine sales improve, beer remains competitive. $21 price target.
downgraded at Soleil to Hold from Buy. $28 price target. Accounting review creates uncertainty around the stock.
downgraded at Thomas Weisel to Market Weight from Overweight on tepid sales growth outlook and potential discontinuation of the CVS relationship. Price target lowered to $30 from $45.
upgraded at UBS. Rating on X was raised from Sell to Neutral. $46 price target. Estimates also boosted, as the tubular segment remains strong and European risks have been priced in.
STOCK COMMENTS / EPS CHANGES
numbers lowered at Goldman through 2012. Company is seeing asset outflows across the board. Neutral rating and new $27 price target.
target reduced at Benchmark to $151. Stronger dollar will hurt the company's business in Europe. Buy rating.
estimate tweaked at Barclays. ARST 2011 EPS estimate lifted to $0.75. Strong 4Q10 results and constructive outlook. Reiterate Equal Weight rating and $25 price target.
estimates tweaked at Barclays. BBY 2011 and 2012 EPS estimates slight raised to $3.55 and $3.82, respectively. Reiterate Overweight rating and $52 price target.
estimates boosted at Goldman. BRS estimates were upped through 2011. Company is performing BP support work. Buy rating and $39 price target.
estimates upped at Morgan Stanley through 2012. Company has returned to normalized earnings growth. Equal-weight rating.
price target boosted at Barclays. EW split adjusted price target raised to $60 based on increased opportunity for its Sapien THV technology. Maintain Overweight rating.
estimates lowered at Morgan Stanley through 2011. Company is seeing a weaker M&A market. Underweight rating and $83 price target.
estimates, target cut at Morgan Stanley. Shares of LAZ now seen reaching $42. Estimates also reduced, giveng recent weakness in the M&A and equity markets. Equal-weight rating.
price target lower at BofA/Merrill by a dollar to $79 on foreign exchange headwinds. Maintain Buy rating.
estimates increased at UBS through 2012. Company posted a strong quarter and is seeing good momentum across the board. Neutral rating and $14 price target.
estimates lower at Barclays. RSH 2010 and 2011 EPS estimates trimmed to $1.87 and $2.05, respectively. Mobile momentum continues. Maintain Overweight rating and $26 price target.
estimates, target raised at UBS. Shares of SBUX now seen reaching $32. Estimates also increased, given better expected consumer products sales. Buy rating.
This article was written by a staff member of TheStreet.com.